Navigation Links
Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
Date:8/19/2007

VALLEY COTTAGE, New York, August 15 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the acquisition, development and commercialization of therapeutics for the treatment of unmet medical needs, particularly neuropathic pain and hepatitis C, today announced its has posted to shareholders a notice convening its AGM and EGM. The AGM and EGM will take place at the Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 4:00 p.m. Israel time, and 4:30pm Israel time, respectively, on September 25, 2007.

At the AGM it is proposed that:

- the annual reports for the year ended 31 December 2006 be received;

- Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the Company's auditors and the fixing of their remuneration be authorized; and

- Messrs Michael Weiss, Ben Zion Weiner and William Kennedy be re-appointed as Directors of the Company.

At the EGM it is proposed that:

- the registered share capital of the Company be increased from 300,000,000 Ordinary Shares to 500,000,000 Ordinary Shares, NIS 0.02 nominal value each; and

- the listing of the Company's Ordinary Shares on the Official List of the United Kingdom Listing Authority be cancelled.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-845-267-0707 ext. 225

+972-8-930-4444


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd

Copyright©2007 PR Newswire.

Related biology technology :

1. NameProtect releases annual list of top trademarkers
2. Doyle says new contracts saving state more than $16 million annually
3. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
4. Annual Bioethics Forum to explore genetic testing
5. Annual Conference Honors Tech Grant Winners
6. General Notes on Primer Design in PCR*
7. General Considerations for Successful Transfection Experiments
8. Real-Time PCR: General Considerations, Rev A
9. AG accuses BioCATT of violating meetings law
10. VC trends, company progress discussed at Mason Wells portfolio meeting
11. Beware the Dreaded Off-Site Technology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)...  Agriculture technology company Cool Planet has closed on ... to commercialize its Cool Terra and Cool Fauna Engineered ... that are simultaneously profitable as well as sustainable and ... months. This latest round of funding was led by ... The company,s primary product, Cool Terra, can improve ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
(Date:3/22/2017)... The global chronic kidney disease ... by Transparency Market Research (TMR). The top four players, ... Inc., accounted for a share of only 41.4% in ... market are focusing aggressively on mergers, acquisitions, and strategic ... to lead to market consolidation in the next few ...
(Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named a ... , Hunt Scanlon Media is one of the most respected life science publications in ... capital sector. , “It is a great honor for Slone Partners to be part ...
Breaking Biology Technology:
(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
(Date:3/7/2017)... 7, 2017 Brandwatch , the leading social intelligence ... Prince,s Trust to uncover insights to support its reporting, help ... The UK,s leading youth charity will be using Brandwatch Analytics ... get a better understanding of the topics and issues that are ... ...
Breaking Biology News(10 mins):